Jan 17 (Reuters) - The U.S. government has awarded Moderna MRNA.O $590 million to advance the late-stage development of its mRNA bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in humans.
The award, funded by the Department of Health and Human Services, would be used to accelerate the development of mRNA-based pandemic influenza vaccines, a company spokesperson said on Friday.
The award was made through the Rapid Response Partnership Vehicle (RRPV) Consortium with funding from the U.S. Biomedical Advanced Research and Development Authority.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.